GGrantIndex
← Leaderboards

Keping Xie

University Of Texas Md Anderson Can Ctr

$7,782,417
Attributed
$7,782,417
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY200516
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$7,782,417 · 8

By mechanism

R01$7,511,373 · 7
R21$271,044 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Base

Research focus

BaseMalignant Neoplasm Of PancreasMolecularPathway InteractionsTissuesGeneticEpigenetic ProcessDesignGrowthResourcesNeoplasm MetastasisSignal TransductionLeadInvestigationMalignant PhenotypeMediatingMolecular TargetOverexpressionClinically SignificantPathogenesisPancreasTranscription FactorProteinsPublic Health Relevance

Grant awards (28)

Clinical Significance of Pancreatic Cancer Differentiation and Dedifferentiation$366,000
R01 · FY2016 · CA · contact PI
Integrated Signaling in Pancreatic Cancer Progression$366,000
R01 · FY2016 · CA · contact PI
Molecular Mediators of Pancreatic Cancer Invasion and Progression$332,000
R01 · FY2016 · CA · contact PI
Clinical Significance of Pancreatic Cancer Differentiation and Dedifferentiation$366,000
R01 · FY2015 · CA · contact PI
Molecular Mediators of Pancreatic Cancer Invasion and Progression$332,000
R01 · FY2015 · CA · contact PI
Molecular Mediators of Pancreatic Cancer Invasion and Progression$322,040
R01 · FY2014 · CA · contact PI
Functional Validation of Pancreatic Cancer Progression Biomarker$308,475
R01 · FY2014 · CA · contact PI
Genetic Approaches to Pancreatic Cancer Progression$246,779
R01 · FY2014 · CA · contact PI
Molecular Mediators of Pancreatic Cancer Invasion and Progression$332,000
R01 · FY2013 · CA · contact PI
Functional Validation of Pancreatic Cancer Progression Biomarker$298,934
R01 · FY2013 · CA · contact PI
Genetic Approaches to Pancreatic Cancer Progression$239,147
R01 · FY2013 · CA · contact PI
Functional Validation of Pancreatic Cancer Progression Biomarker$318,015
R01 · FY2012 · CA · contact PI
Genetic Approaches to Pancreatic Cancer Progression$254,412
R01 · FY2012 · CA · contact PI
KLF4 Genetic and Epigenetic Changes in Human Pancreatic Cancer$247,971
R01 · FY2012 · CA · contact PI
Functional Validation of Pancreatic Cancer Progression Biomarker$318,015
R01 · FY2011 · CA · contact PI
Genetic Approaches to Pancreatic Cancer Progression$254,412
R01 · FY2011 · CA · contact PI
KLF4 Genetic and Epigenetic Changes in Human Pancreatic Cancer$247,971
R01 · FY2011 · CA · contact PI
Functional Validation of Pancreatic Cancer Progression Biomarker$327,850
R01 · FY2010 · CA · contact PI
Genetic Approaches to Pancreatic Cancer Progression$262,280
R01 · FY2010 · CA · contact PI
KLF4 Genetic and Epigenetic Changes in Human Pancreatic Cancer$255,640
R01 · FY2010 · CA · contact PI
Molecular basis of pancreatic cancer progression and metastsis$135,522
R21 · FY2010 · CA · contact PI
KLF4 Genetic and Epigenetic Changes in Human Pancreatic Cancer$255,640
R01 · FY2009 · CA · contact PI
Molecular basis of pancreatic cancer progression and metastsis$135,522
R21 · FY2009 · CA · contact PI
KLF4 Genetic and Epigenetic Changes in Human Pancreatic Cancer$255,640
R01 · FY2008 · CA · contact PI
Antitumor Activity of Inducible Nitric Oxide Synthase$251,038
R01 · FY2005 · CA
Antitumor Activity of Inducible Nitric Oxide Synthase$251,038
R01 · FY2004 · CA
Antitumor Activity of Inducible Nitric Oxide Synthase$251,038
R01 · FY2003 · CA
Antitumor Activity of Inducible Nitric Oxide Synthase$251,038
R01 · FY2002 · CA